TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN) today announced that it will present aspects of its immune
checkpoint related research at two scientific conferences this month.
On February 9, Arthur Machlenkin, PhD, Head of Immunology Group at
Compugen, will deliver an oral presentation at the Keystone
Symposia: Tumor Immunology - Multidisciplinary Science Driving
Combination Therapy being held from February 8-13, in Banff, Canada.
In his talk titled Identification of Novel Immuno-Modulatory Targets
for Cancer Immunotherapy, Dr. Machlenkin will discuss Compugen’s
discovery approach in identifying 11 novel immune checkpoint candidates
for cancer immunotherapy. In addition, Dr. Machlenkin will present
experimental data demonstrating the immunomodulatory function and
expression patterns of two Compugen-discovered immune checkpoints:
CGEN-15049 and CGEN-15027.
On February 16, Ofer Levy, PhD, Principal Scientist at Compugen, will
deliver a presentation titled Computational Discovery and
Experimental Validation of Novel Players in the Immuno-Oncology Arena
at the Onco-Immunology Meeting: Prospects of Immunity for Precision
Cancer Medicine, to be held at the Israel Institute of Advanced Studies,
in Jerusalem, Israel. In his talk Dr. Levy will give an overview on the
design and implementation of immune assays aimed at exploring the
potential role of Compugen’s novel targets as immune checkpoint
candidates.
About Compugen
Compugen is a leading drug discovery company focused on monoclonal
antibodies and therapeutic proteins to address important unmet needs in
the fields of oncology and immunology. The Company utilizes a broad and
continuously growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug target
candidates, which are then advanced in its Pipeline Program. The
discovery and development of monoclonal antibody therapeutic candidates
against selected Compugen-discovered novel target candidates is
performed by Compugen’s wholly-owned U.S. subsidiary located in South
San Francisco. The Company's business model includes collaborations
covering the further development and commercialization of product
candidates at various stages from its Pipeline Program and various forms
of research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of terminology
such as “will,” “may,” “expects,” “anticipates,” “believes,” and
“intends,” and describe opinions about future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these and other factors are
discussed in the "Risk Factors" section of Compugen’s most recent Annual
Report on Form 20-F as filed with the Securities and Exchange Commission
as well as other documents that may be subsequently filed by Compugen
from time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen’s views only
as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements unless
required by law.